These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

411 related items for PubMed ID: 9130610

  • 1. Fas receptor (CD95)-mediated apoptosis in leukemic cells.
    Komada Y, Sakurai M.
    Leuk Lymphoma; 1997 Mar; 25(1-2):9-21. PubMed ID: 9130610
    [Abstract] [Full Text] [Related]

  • 2. Fas receptor (CD95)-mediated apoptosis is induced in leukemic cells entering G1B compartment of the cell cycle.
    Komada Y, Zhou YW, Zhang XL, Xue HL, Sakai H, Tanaka S, Sakatoku H, Sakurai M.
    Blood; 1995 Nov 15; 86(10):3848-60. PubMed ID: 7579353
    [Abstract] [Full Text] [Related]

  • 3. On the role and significance of Fas (Apo-1/CD95) ligand (FasL) expression in immune privileged tissues and cancer cells using multiple myeloma as a model.
    Greil R, Egle A, Villunger A.
    Leuk Lymphoma; 1998 Nov 15; 31(5-6):477-90. PubMed ID: 9922038
    [Abstract] [Full Text] [Related]

  • 4. Fas/APO-1 (CD95)-mediated cytotoxicity is responsible for the apoptotic cell death of leukaemic cells induced by interleukin-2-activated T cells.
    Komada Y, Zhou YW, Zhang XL, Chen TX, Tanaka S, Azuma E, Sakurai M.
    Br J Haematol; 1997 Jan 15; 96(1):147-57. PubMed ID: 9012700
    [Abstract] [Full Text] [Related]

  • 5. Fas receptor-Fas ligand system is independent of both CD34 status and chemosensitivity in acute myeloid leukemia.
    Lewis NR, Pallis M, Russell NH.
    Exp Hematol; 2000 May 15; 28(5):535-42. PubMed ID: 10812243
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Etoposide-induced apoptosis is not associated with the fas pathway in acute myeloblastic leukemia cells.
    Siitonen T, Mäntymaa P, Säily M, Savolainen E, Koistinen P.
    Leuk Res; 2000 Apr 15; 24(4):281-8. PubMed ID: 10713325
    [Abstract] [Full Text] [Related]

  • 10. Enhancement of susceptibility to Fas-mediated apoptosis of TH1 cells by nonmitogenic anti-CD3epsilon F(ab')2.
    Yu XZ, Anasetti C.
    Transplantation; 2000 Jan 15; 69(1):104-12. PubMed ID: 10653388
    [Abstract] [Full Text] [Related]

  • 11. Dissociation of Fas-mediated cytotoxicity and FasL expression in a cytotoxic CD4+ T-cell clone. Comparative analysis of Fas-mediated cytotoxicity between a T-hybridoma and a T-cell clone.
    Kaneda R, Iwabuchi K, Onoé K.
    Immunol Lett; 1997 Jan 15; 55(1):53-60. PubMed ID: 9093882
    [Abstract] [Full Text] [Related]

  • 12. Functional significance of adhesion molecules in Fas-dependent apoptotic cell death induced by interleukin-2-activated T cells.
    Zhou YW, Komada Y, Inaba H, Deguchi T, Sugiyama K, Azuma E, Sakurai M.
    Immunol Invest; 1998 Jan 15; 27(4-5):309-22. PubMed ID: 9730091
    [Abstract] [Full Text] [Related]

  • 13. Membrane-bound Fas (Apo-1/CD95) ligand on leukemic cells: A mechanism of tumor immune escape in leukemia patients.
    Buzyn A, Petit F, Ostankovitch M, Figueiredo S, Varet B, Guillet JG, Ameisen JC, Estaquier J.
    Blood; 1999 Nov 01; 94(9):3135-40. PubMed ID: 10556200
    [Abstract] [Full Text] [Related]

  • 14. Functional expression of Fas (CD95) in acute myeloid leukemia cells in the context of CD34 and CD38 expression: possible correlation with sensitivity to chemotherapy.
    Iijima N, Miyamura K, Itou T, Tanimoto M, Sobue R, Saito H.
    Blood; 1997 Dec 15; 90(12):4901-9. PubMed ID: 9389707
    [Abstract] [Full Text] [Related]

  • 15. Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape.
    Hahne M, Rimoldi D, Schröter M, Romero P, Schreier M, French LE, Schneider P, Bornand T, Fontana A, Lienard D, Cerottini J, Tschopp J.
    Science; 1996 Nov 22; 274(5291):1363-6. PubMed ID: 8910274
    [Abstract] [Full Text] [Related]

  • 16. Cell death induced by the Fas/Fas ligand pathway and its role in pathology.
    Waring P, Müllbacher A.
    Immunol Cell Biol; 1999 Aug 22; 77(4):312-7. PubMed ID: 10457197
    [Abstract] [Full Text] [Related]

  • 17. Differential regulation of CD95 (Fas/APO-1) expression in human blood eosinophils.
    Luttmann W, Opfer A, Dauer E, Foerster M, Matthys H, Eibel H, Schulze-Osthoff K, Kroegel C, Virchow JC.
    Eur J Immunol; 1998 Jul 22; 28(7):2057-65. PubMed ID: 9692873
    [Abstract] [Full Text] [Related]

  • 18. Human melanoma-reactive CD4+ and CD8+ CTL clones resist Fas ligand-induced apoptosis and use Fas/Fas ligand-independent mechanisms for tumor killing.
    Rivoltini L, Radrizzani M, Accornero P, Squarcina P, Chiodoni C, Mazzocchi A, Castelli C, Tarsini P, Viggiano V, Belli F, Colombo MP, Parmiani G.
    J Immunol; 1998 Aug 01; 161(3):1220-30. PubMed ID: 9686582
    [Abstract] [Full Text] [Related]

  • 19. Fas-mediated suicide of tumor-reactive T cells following activation by specific tumor: selective rescue by caspase inhibition.
    Zaks TZ, Chappell DB, Rosenberg SA, Restifo NP.
    J Immunol; 1999 Mar 15; 162(6):3273-9. PubMed ID: 10092779
    [Abstract] [Full Text] [Related]

  • 20. Effect of IL-12 on TNF-alpha-mediated osteoclast formation in bone marrow cells: apoptosis mediated by Fas/Fas ligand interaction.
    Kitaura H, Nagata N, Fujimura Y, Hotokezaka H, Yoshida N, Nakayama K.
    J Immunol; 2002 Nov 01; 169(9):4732-8. PubMed ID: 12391181
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.